Physician profile
Mitchell W Smith
NPI 1700101102
$32,621.86
in general payments reported to CMS, 2019-2025
36 companies · $19K in 2025
The $19K reported for 2025 was more than what 92% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,796 · 2020: $304 · 2021: $2,235 · 2022: $849 · 2023: $2,894 · 2024: $1,077 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $4,332 · Travel and Lodging: $2,393 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,312 · Education: $63.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,337.50 |
| Food and Beverage | $4,331.67 |
| Travel and Lodging | $2,393.27 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,312.00 |
| Education | $63.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $18,076.13 | 2019-2025 | |
| Dermira, INC. | $5,533.64 | 2019 | |
| Genzyme Corporation | $2,700.60 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,516.58 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Genentech USA, INC. | $1,448.29 | 2019-2025 | Xolair |
| Glaxosmithkline, LLC. | $690.51 | 2019-2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $299.68 | 2021-2025 | Eohilia, Takhzyro, Cuvitru |
| Regeneron Healthcare Solutions, INC. | $261.30 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $195.39 | 2021-2025 | Xembify |
| Csl Behring | $185.85 | 2019-2025 | Hizentra, Andembry |
| Galderma Laboratories, L.P. | $177.64 | 2025 | Nemluvio |
| Blueprint Medicines Corporation | $175.03 | 2023-2024 | Ayvakit |
| Amgen INC. | $124.67 | 2023-2025 | Tezspire |
| Abbvie INC. | $120.39 | 2022-2025 | Rinvoq |
| Biocryst US Sales Co., LLC | $110.89 | 2021-2024 | Orladeyo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $95.56 | 2025 | Neffy |
| Pharming Healthcare, INC. | $94.78 | 2022-2025 | Ruconest |
| Pfizer INC. | $93.83 | 2020-2025 | |
| Octapharma USA, INC. | $93.15 | 2023-2025 | Cutaquig |
| Kaleo, INC. | $76.86 | 2019-2023 | Auvi-Q |
| Ionis Pharmaceuticals, INC. | $72.98 | 2025 | Donidalorsen, Dawnzera |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.33 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $49.92 | 2022-2023 | Airduo Digihaler |
| Verona Pharma, INC. | $46.58 | 2025 | Ohtuvayre |
| Incyte Corporation | $44.23 | 2023-2025 | Opzelura |
| Bio Products Laboratory USA, INC. | $43.54 | 2022-2023 | Coagadex, Gammaplex |
| Leo Pharma INC. | $43.18 | 2022-2025 | Adbry |
| Phathom Pharmaceuticals, INC. | $25.34 | 2024 | Voquezna |
| Azurity Pharmaceuticals, INC. | $25.11 | 2025 | Alvesco |
| Hikma Pharmaceuticals USA | $24.02 | 2024 | Ryaltris |
| Alk-Abello, INC | $23.46 | 2020 | |
| Lilly USA, LLC | $20.46 | 2025 | Ebglyss |
| Hospira, INC. | $20.39 | 2024 | |
| Shire North American Group INC | $14.87 | 2019 | |
| Circassia INC. | $13.13 | 2019 | |
| Optinose US, INC. | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.